BULLETIN FROM MOBERG PHARMA’S ANNUAL GENERAL MEETING 2014

STOCKHOLM, May 11, 2015. Moberg Pharma AB’s (“Company”) Annual General Meeting
took place on Monday, May 11, 2015 in the Company´s premises in Bromma.
Adoption of the income statements and the balance sheets
The Annual General Meeting (the “Meeting”) approved the income statements and
the balance sheets for the fiscal year 2014.

The Meeting resolved, in accordance with the proposal of the Board of Directors,
that no dividend should be paid for the fiscal year 2014.

The Meeting discharged the Board members and the Chief Executive Officer from
liability for the fiscal year 2014.

Board of Directors
In accordance with the proposal of the Nomination Committee, the Meeting
resolved that the Board of Directors shall consist of seven persons and no
deputies. The Meeting resolved re-election of the Board Directors Mats
Pettersson, Wenche Rolfsen, Torbjörn Koivisto, Geert Cauwenbergh and Thomas B.
Thomsen. Further, the Meeting appointed Thomas Eklund and Mattias Klintemar as
Board Directors. Mats Pettersson was re-elected as Chairman of the Board of
Directors.

The Meeting resolved that an aggregate fee to Board members of SEK 1,250,000
shall be paid, of which SEK 300,000 to the Chairman and SEK 150,000 for all
members elected by the Annual General Meeting. It was also resolved that an
additional fee of SEK 50,000 shall be paid to the Chairman of the Compensation
Committee.

Fees to the Auditors, for a period until the end of the next Annual General
Meeting, are to be paid as per approved invoice.

Nomination Committee
The Meeting resolved, in accordance with the proposal of the Nomination
Committee, that the Company shall have a Nomination Committee consisting of four
members. The Nomination Committee shall comprise one representative of each of
the three largest shareholders or owner groups in the Company in terms of votes
as per September 30, 2015, besides the Chairman of the Board of Directors.

Principles for remuneration
The Meeting resolved to approve the Board of Director’s proposal for principles
of remuneration to senior executives in Moberg Pharma.

Employee Stock Option Plan 2015
In accordance with the Board of Directors’ revised proposal, the Meeting
resolved to adopt an employee stock option plan for employees in the Company in
the Company and in the Company’s wholly-owned subsidiary Moberg Pharma North
America LLC. It will be permissible to allot a maximum of 150,000 employee stock
options per plan participant. The Board of Directors and the Chief Executive
Officer shall decide which persons shall be encompassed by the Employee Stock
Option Plan based on position, qualification and individual performance. The
employee stock option plan will include the following senior executives in the
Company; Anna Ljung, Kjell Rensfeldt, Martin Ingman and Jeff Vernimb. The three
first mentioned are proposed to be allotted 25,000 employee stock options each
and Jeff Vernimb is proposed to be allotted 150,000 employee stock options. In
order to secure the Company’s commitments under the employee stock option plan,
the Meeting resolved on an issue of a maximum 326,739 warrants to the Company’s
wholly-owned subsidiary Moberg Derma Incentives AB, whereof maximum 38,239 of
the warrants are intended to hedge the costs (mainly social security
contributions or corresponding taxes) that may arise from the employee stock
option plan. In addition the Meeting resolved to approve that the subsidiary is
entitled to transfer warrants or shares in the Company to the participants in
the employee stock option plan, or otherwise dispose of the warrants, in order
to secure the Company’s commitments and costs in connection with the employee
stock option plan. In the event that all warrants issued in respect of Employee
Stock Option Plan 2015 are used to subscribe for new shares, the Company’s share
capital will increase by SEK 32,673.90 from SEK 1,396,253.70 to SEK
1,428,297.60. This is equivalent to a dilution of approximately two per cent of
the shares and votes in the Company.

Authorization to issue share
The Meeting resolved, in accordance with the proposal of the Board of Directors,
to authorize the Board of Directors to, within the scope of the articles of
association, with or without deviation from the shareholders’ preferential
right, on one or several occasions during the period until the next Annual
General Meeting, resolve to increase the Company’s share capital by issuing new
shares in the Company. The total number of shares issued in accordance with this
authorization may be equivalent to a maximum of 20 per cent of the shares in the
Company at the time of the 2015 Annual General Meeting.

About this information
Moberg Pharma discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 7:30 pm (CET) on May 11th, 2015.
For further information, please contact:
Peter Wolpert, President and CEO
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35
E-mail: peter.wolpert@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex®, Jointflex®, Domeboro®, Vanquish®, and Fergon®. Kerasal
Nail®(Emtrix®or Nalox™ in certain ex-U.S. markets) is a leading OTC treatment of
nail disorders in the U.S., Canada and several EU markets and is currently being
launched in Southeast Asia. The company is growing organically as well as
through acquisitions. Internal development programs focuses on innovative drug
delivery of proven compounds and include two phase II assets, MOB-015
(onychomycosis) and BUPI (oral mucositis). Moberg Pharma has offices in
Stockholm and New Jersey and the company’s shares are listed on the Small Cap
list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). For further
information, please visit: www.mobergpharma.com